



Erratum for Brunschwig et al., “UCT943, a Next-Generation *Plasmodium falciparum* PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria”

Christel Brunschwig,^a Nina Lawrence,^a Dale Taylor,^a Efrem Abay,^a Mathew Njoroge,^a Gregory S. Basarab,^a Claire Le Manach,^b Tanya Paquet,^b Diego González Cabrera,^b Aloysius T. Nchinda,^b Carmen de Kock,^a Lubbe Wiesner,^c Paolo Denti,^c David Waterson,^d Benjamin Blasco,^d Didier Leroy,^d Michael J. Witty,^d Cristina Donini,^d James Duffy,^d Sergio Wittlin,^{e,f} Karen L. White,^g Susan A. Charman,^g Maria Belén Jiménez-Díaz,^h Iñigo Angulo-Barturen,^h Esperanza Herreros,^h Francisco Javier Gamo,^h Rosemary Rochford,ⁱ Dalu Mancama,^j Theresa L. Coetzer,^k Mariëtte E. van der Watt,^l Janette Reader,^l Lyn-Marie Birkholtz,^l Kennan C. Marsh,^m Suresh M. Solapure,^{n†} John E. Burke,^z Jacob A. McPhail,^z Manu Vanaerschot,^o David A. Fidock,^{o,p} Paul V. Fish,^q Peter Siegl,^r Dennis A. Smith,^s Grennady Wirjanata,^t Rintis Noviyanti,^u Ric N. Price,^{t,v} Jutta Marfurt,^t Kigbafori D. Silue,^w Leslie J. Street,^b Kelly Chibale^{b,x,y}

^aDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa

^bDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa

^cDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa

^dMedicines for Malaria Venture, Geneva, Switzerland

^eSwiss Tropical and Public Health Institute, Basel, Switzerland

^fUniversity of Basel, Basel, Switzerland

^gCentre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria, Australia

^hGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain

ⁱDepartment of Immunology and Microbiology, University of Colorado, Aurora, Colorado, USA

^jBiosciences, Council for Scientific and Industrial Research, Pretoria, South Africa

^kPlasmodium Molecular Research Unit, Wits Research Institute for Malaria, Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa

^lDepartment of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa

^mAbbVie, North Chicago, Illinois, USA

ⁿNagarjuna Gardens, Bangalore, India

^oDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA

^pDivision of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, New York, USA

^qAlzheimer's Research UK UCL Drug Discovery Institute, Faculty of Brain Sciences, University College London, London, United Kingdom

^rSiegl Pharma Consulting LLC, Blue Bell, Pennsylvania, USA

^sIndependent Researcher, Walmer, Kent, United Kingdom

^tGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia

^uEijkman Institute for Molecular Biology, Jakarta, Indonesia

^vCentre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

^wCentre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire

^xInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, South Africa

^ySouth African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, South Africa

^zDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada

Citation Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, González Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz L-M, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K. 2018. Erratum for Brunschwig et al., “UCT943, a next-generation *Plasmodium falciparum* PI4K inhibitor preclinical candidate for the treatment of malaria.” *Antimicrob Agents Chemother* 62:e01941-18. <https://doi.org/10.1128/AAC.01941-18>.

Copyright © 2018 American Society for Microbiology. All Rights Reserved. Address correspondence to Kelly Chibale, kelly.chibale@uct.ac.za.

† Deceased.

Volume 62, no. 9, e00012-18, 2018, <https://doi.org/10.1128/AAC.00012-18>. Page 7: The two dots indicating the ranking of UCT943 and MMV048 in the developability classification system (DCS) are missing from Fig. 4. The correct figure is shown below.

